Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetic diet

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    136 result(s) found for: Diabetic diet. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2008-000786-32 Sponsor Protocol Number: SPP301CRD21 Start Date*: 2008-06-17
    Sponsor Name:Speedel Pharma Ltd
    Full Title: A Randomised, Double-blind, Placebo-Controlled, Dose-ranging, Parallel Design Study to Evaluate the Efficacy and Safety of the Endothelin Antagonist Avosentan in Patients With Diabetic Kidney Disease
    Medical condition: Diabetic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012687 Diabetic renal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) LV (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005032-33 Sponsor Protocol Number: 70242 Start Date*: 2009-01-22
    Sponsor Name:Gedeon Richter Plc.
    Full Title: Single center, exploratoric, double-blind, placebo controlled study to investigate the efficacy and tolerability of vinpocetine in patients with non-proliferative diabetic retinopathy
    Medical condition: Patients with type 2 diabetes mellitus with mild or moderate or severe non-proliferative diabetic retinopathy (NPDR).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054109 Non-proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-002480-98 Sponsor Protocol Number: MT-3995-E06 Start Date*: 2012-10-26
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral...
    Medical condition: Type II Diabetes Mellitus with Nephropathy and Albuminuria
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-003332-23 Sponsor Protocol Number: B1261007 Start Date*: 2013-03-21
    Sponsor Name:Pfizer Inc., 235 42nd Street, New York, NY 10017, USA
    Full Title: A phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonis...
    Medical condition: Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-005482-12 Sponsor Protocol Number: GLP-1-2012-01 Start Date*: 2013-04-15
    Sponsor Name:University College Dublin
    Full Title: The effect of glucagon-like-peptide 1 (GLP-1) analogues on inflammation in humans with diabetic kidney disease.
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10012687 Diabetic renal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005985-10 Sponsor Protocol Number: PTF-REN-001 Start Date*: 2008-03-03
    Sponsor Name:Juan Francisco Navarro González
    Full Title: Análisis del Efecto Renoprotector de la Pentoxifilina en Pacientes con Enfermedad Renal Crónica Secundaria a Nefropatía Diabética
    Medical condition: Enfermedad renal crónica secundaria a nefropatía diabética.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061835 Diabetic nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002095-15 Sponsor Protocol Number: KRX-101-401 Start Date*: 2005-10-12
    Sponsor Name:Keryx Biopharmaceuticals, Inc.
    Full Title: The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy
    Medical condition: Overt Type 2 Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061835 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001267-49 Sponsor Protocol Number: CL005_140 Start Date*: 2011-10-25
    Sponsor Name:ChemoCentryx, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001641-24 Sponsor Protocol Number: PYR-311 Start Date*: 2014-09-29
    Sponsor Name:NephroGenex
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin® (pyridoxamine dihydrochloride) in Subjects With Nephropathy Due to Type ...
    Medical condition: Nephropathy Due to Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005024-40 Sponsor Protocol Number: NPP100023 Start Date*: 2005-04-06
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LAMOTRIGINE 200-400MG/DAY COMPARED WITH PLACEBO IN SUBJECTS WITH PAINFUL DIA...
    Medical condition: Painful Diabetic Neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006191-38 Sponsor Protocol Number: 004SC06084 Start Date*: 2007-01-11
    Sponsor Name:ANGELINI
    Full Title: The effects of the association bindarit irbesartan versus irbesartan alone on albuminuria of patients with Diabetic Nephropathy. Placebo-controlled study.
    Medical condition: Patients with type II diabetes with nephropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047065 Vascular disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2008-004794-18 Sponsor Protocol Number: KF6005/02 Start Date*: 2009-01-22
    Sponsor Name:Grünenthal GmbH
    Full Title: A randomized Phase IIa trial evaluating the safety and efficacy of a new centrally acting analgesic in subjects with pain due to diabetic polyneuropathy
    Medical condition: painful diabetic polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012685 Diabetic polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000087-12 Sponsor Protocol Number: DXV406 Start Date*: 2005-08-16
    Sponsor Name:Amersham Health S.A. (parte de GE Healthcare Ltd y sus filiales)
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, en fase IV, para comparar los efectos renales del medio de contraste no iónico isosmolar, iodixanol 320 mg I/ml (VisipaqueTM),...
    Medical condition: Subjects with a combination of diabetes mellitus (type I or II), and impaired renal function.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061835 Pt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002902-74 Sponsor Protocol Number: EML 017008-004 Start Date*: 2006-07-21
    Sponsor Name:Merck Santé s.a.s.
    Full Title: A double-blind, double-dummy, randomized, controlled, multi-centre study of the activity and safety of 2 daily doses of EMD 387008 versus placebo and metformin in parallel groups after 8 weeks of t...
    Medical condition: Phase II study on type 2 diabetic subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2012-002481-12 Sponsor Protocol Number: MT-3995-E07 Start Date*: 2012-09-07
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral...
    Medical condition: Type II Diabetes Mellitus with nephropathy and Albuminuria'
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001639-35 Sponsor Protocol Number: CRFB002DDE25 Start Date*: 2014-08-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu...
    Medical condition: Visual impairment due to diabetic macula edema
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004877-24 Sponsor Protocol Number: RFB002D2301 Start Date*: 2008-07-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Completed) HU (Completed) BE (Completed) IT (Completed) NL (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018852-29 Sponsor Protocol Number: CRFB002DDE13 Start Date*: 2010-06-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 12-month, two-armed, randomized, double-masked, multicenter, Phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to Ranibizumab intravitreal injections vs. ...
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005727-80 Sponsor Protocol Number: EMPA Start Date*: Information not available in EudraCT
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: Effect of insulin on renal maximum glucose transport capacity: interaction with empagliflozin. A not randomized pilot study.
    Medical condition: Patients with diabetes mellitus type 2
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019795-74 Sponsor Protocol Number: CRFB002D2304 Start Date*: 2010-10-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs. 0.5 mg ranibi...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) FR (Completed) ES (Completed) HU (Completed) IT (Completed) IE (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 16:45:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA